Frontlight ResearchEarly access
Myasthenia gravis trials in Denmark
8 of 8 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleSafety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients with Myasthenia Gravis
- Where
- Aarhus N, Copenhagen Oe
- Age
- 18 years and over
- People
- 59 worldwide
- Run by
- NMD Pharma A/S
See details and how to join2023-507539-40-00 - Phase 3Taking peopleStudy to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Where
- Copenhagen Oe
- Age
- 18 years to 80 years
- People
- 231 worldwide
- Run by
- Immunovant Sciences GmbH
See details and how to joinNCT07039916 · EU 2024-515979-35-00 - Phase 3CompletedA Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- Where
- Aalborg, Copenhagen Oe
- Age
- 18 years and over
- People
- 199 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT04951622 · EU 2023-504152-97-00 - No phaseNot yet taking people in DenmarkHolistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360
- Where
- Aarhus, Copenhagen
- Age
- 18 years and over
- People
- 100 worldwide
- Run by
- Ad scientiam
See details and how to joinNCT07323316 - Phase 3Not yet taking people in DenmarkA Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
- Where
- Copenhagen, Gistrup
- Age
- 18 years to 80 years
- People
- 195 worldwide
- Run by
- Dianthus Therapeutics
See details and how to joinNCT07647510 · EU 2026-525298-38-00 - Phase 1/2Not yet taking people in DenmarkA Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients with Generalized Myasthenia Gravis
- Where
- Copenhagen Oe
- Age
- 18 years and over
- People
- 38 worldwide
- Run by
- Aurinia Pharmaceuticals Inc.
See details and how to join2025-525127-27-00 - Phase 1/2WithdrawnA double-blind, randomised, placebo-controlled, first-in-human (FIH) Phase I/IIa, multi-centre trial to assess safety, tolerability, and immune response of single and multiple ascending doses of TOL2 (Immune Tolerising Agent) in patients with generalised myasthenia gravis
- Where
- Copenhagen Oe
- Age
- 18 years and over
- People
- 55 worldwide
- Run by
- Bonsai Biotherapeutics AB
See details and how to join2024-515627-10-00 - Phase 2Taking peopleSafety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
- Where
- Aarhus, Copenhagen
- Age
- 18 years and over
- People
- 84 worldwide
- Run by
- NMD Pharma A/S
See details and how to joinNCT06414954